Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 44 (TRAJ44) refers to a specific **joining (J) gene segment** within the T cell receptor alpha (TRA) locus. TRAJ44 encodes part of the J region that, through somatic recombination, helps generate the vast diversity of T cell receptor (TCR) alpha chains. A T cell receptor is composed of an alpha (TRA) and beta (TRB) chain heterodimer; each chain is constructed from variable (V), joining (J), and, for the beta chain, diversity (D) segments, facilitating antigen recognition when complexed with major histocompatibility complex (MHC) molecules on the cell surface. TRAJ44 itself does not form a protein with direct signaling or ligand-binding function but rather participates as a genetic component in the assembly of the TCR alpha chain, essential for T cell-mediated immunity. It is not considered a direct therapeutic target or independent receptor; instead, it is a **gene segment** required for the proper function and diversity of TCRs[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 44 (TRAJ44).